Tag: stage

Falcon Oil & Gas Ltd (“Falcon”)

SEOUL, South Korea, July 13, 2025 (GLOBE NEWSWIRE) -- Sometimes, the most remarkable culinary revolutions happen not with bold innovations, but with quiet refinements. As European premium meats enter Korean kitchens, they introduce new depths of purity, flavor, and responsibility to recipes long cherished.

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies

New York City, NY, July 13, 2025 (GLOBE NEWSWIRE) -- As the global regulatory environment becomes clearer, cryptocurrencies are entering a rapid development stage. ALL4 Mining, a compliant cloud mining platform headquartered in the UK, has officially launched a new AI smart mining system that supports a variety of mainstream digital assets such as Bitcoin (BTC), Ethereum (ETH), and Ripple (XRP), providing users with a legal, safe, and stable daily income plan.

PhenQ 2025 OTC Fat Burner for Men: Medically accredited supplement gains national traction with expert-backed multi-action formula and user trust.

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –

DUBAI, United Arab Emirates, July 12, 2025 (GLOBE NEWSWIRE) -- Little Pepe has formally crossed the $5.5 million mark in its ongoing presale, signaling robust investor interest because it enters Stage 5 with tokens now priced at $0.0014. This milestone underscores the project’s rapid growth and rising credibility in the crypto space.

DUBAI, United Arab Emirate, July 12, 2025 (GLOBE NEWSWIRE) -- Little Pepe, the fast-growing EVM Layer 2 meme coin, has officially surpassed $5.5 million in presale, marking a significant milestone as it enters Stage 5 with tokens now priced at $0.0014.

Kuick Research Report highlights ongoing Clinical Development Technology platforms In Recent Research Study On KIF18A Therapies

CAMBRIDGE, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

EMERYVILLE, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 8, 2025, the compensation committee of the Company’s board of directors granted one new non-executive employee 4,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

WOBURN, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.